GLP-1 receptor agonists were first utilized as second-line hypoglycemic agents, but further studies have shown that GLP-1 has anti-inflammatory and neuroprotective effects, as well as the ability to improve cognitive impairment (Koshal et al., 2018). Here, GLP1R is linked to Cognitive impairment.